Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
Y Chen, Z Yang, Y Wang, M Hu, B Zhang… - Frontiers in …, 2021 - frontiersin.org
Objectives More and more encouraging evidence revealed that immunotherapy could
improve clinical outcomes in patients with previously treated non-small cell lung cancer …
improve clinical outcomes in patients with previously treated non-small cell lung cancer …
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer
B Chen, W Yao, X Li, G Lin, Q Chu, H Liu, Y Du… - British Journal of …, 2024 - nature.com
Background Cadonilimab is a bispecific antibody that simultaneously targets programmed
cell death receptor-1 and cytotoxic T lymphocyte-associated antigen-4. This study aimed to …
cell death receptor-1 and cytotoxic T lymphocyte-associated antigen-4. This study aimed to …
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
S Yuan, L Peng, Y Liu, BG Till, X Yan, J Zhang… - Cancer Immunology …, 2023 - Springer
Background Anti-angiogenic drugs increase anti-tumor efficacy of immune checkpoint
inhibitors (ICIs). However, the optimal dose of anti-angiogenic drugs remains unclear …
inhibitors (ICIs). However, the optimal dose of anti-angiogenic drugs remains unclear …
Combination of anti-PD-1 antibody, anlotinib and pegaspargase “sandwich” with radiotherapy in localized natural killer/T cell lymphoma
P Sun, Y Wang, H Yang, C Chen, M Nie… - Frontiers in …, 2022 - frontiersin.org
Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly
effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) …
effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) …
Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients
Y Feng, L Tang, H Wang, Y Liu, S Yang, L Lin… - Cancer Immunology …, 2023 - Springer
Background To report the efficacy and safety data of immunotherapy plus angiogenic
inhibitors treatment in lung adenocarcinoma patients. Methods Eligible patients with …
inhibitors treatment in lung adenocarcinoma patients. Methods Eligible patients with …
Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
H Lin, C Ma, A Zhong, H Zang, W Chen… - … Chemistry & High …, 2024 - ingentaconnect.com
Background: Anti-angiogenic agents could enhance tumor immunity response, and anti-
angiogenesis plus immunotherapy has become a novel treatment option for advanced non …
angiogenesis plus immunotherapy has become a novel treatment option for advanced non …
Anlotinib enhanced CD8+ T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer
J Luo, K Cheng, X Ji, C Gao, R Zhu, J Chen, W Xue… - Cancer Letters, 2024 - Elsevier
Non-small cell lung cancer (NSCLC) is a leading cause of mortality worldwide and requires
effective treatment strategies. Recently, the development of a novel multiple-target tyrosine …
effective treatment strategies. Recently, the development of a novel multiple-target tyrosine …
Novel nanocrystal injection of insoluble drug anlotinib and its antitumor effects on hepatocellular carcinoma
M Luo, H Sun, Q Jiang, Y Chai, C Li, B Yang… - Frontiers in …, 2021 - frontiersin.org
The molecularly targeted agent anlotinib offers a novel therapeutic strategy against
advanced hepatocellular carcinoma (HCC). With this study, we aimed to solve the technical …
advanced hepatocellular carcinoma (HCC). With this study, we aimed to solve the technical …
[HTML][HTML] Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial
Y Liu, Y Cheng, K Li, J Shi, Y Liu, L Wu… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background In ALTER 1202, anlotinib prolonged the progression-free survival (PFS) and
overall survival (OS) of patients with relapsed small cell lung cancer (SCLC). The aim of this …
overall survival (OS) of patients with relapsed small cell lung cancer (SCLC). The aim of this …
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A …
XJ Dou, RY Ma, DW Ren, Q Liu… - Lung Cancer: Targets and …, 2024 - Taylor & Francis
Objective This study aimed to investigate the effectiveness and tolerability of anlotinib plus
PD-1 blockades in patients with previously immunotherapy treated advanced non-small-cell …
PD-1 blockades in patients with previously immunotherapy treated advanced non-small-cell …